Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURKOVAC vs CoronaVac in Healthy Adults
NCT04942405Phase 3Completed
- Sponsor
- TÜSEB
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of turkovac in coronavirus disease 2019 (COVID-19), sponsored by TÜSEB. Primary endpoint: Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19. Started Jun 2021; status: completed.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04942405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942405.